Available Technologies
# of Displayed Technologies: 4 / 4
Applied Category Filter (Click To Remove): Antibodies
Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
- College: College of Medicine (COM)
- Inventors: Chu, Nam; Le, Nhat
- Licensing Officer: Willson, Christopher
Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 —
A novel monoclonal antibody (PIIO-1) targeting the ligand-free form of GARP, the non-signaling docking receptor for TGFβ. PIIO-1 distrupts transforming growth factor-β (TGF-β) signalling in the tumor microenvironment, primarily on T regulatory cells, consequently augmenting anti-tumor immunity and overcoming ICB resistance . Unlike market competitors, ABBV-151 and DS-1055a which bind the TGF-β1/GARP complex, PIIO-1 prevents activation of all 3 TGF-β isoforms, avoiding isoform compensation and avoiding the potential on-target, adverse effects of binding the TGF-β1/GARP complex found on platelets.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the activation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by induci…
- College: College of Medicine (COM)
- Inventors: Li, Zihai
- Licensing Officer: He, Panqing
Potential uses of IgG Fc for treating human diseases
TS-036778 —
Infectious diseases present a problem for treatment, with concerns for the overuse of antibiotic medicine, inefficiency of modern medicines, and a need in the market for novel technologies that will target and work in conjunction with the host immune system, rather than depending on external mecha…
- College: College of Medicine (COM)
- Inventors: Dai, Hongsheng; Caligiuri, Michael; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
Anti-NCL Immunoagent for Cancer Diagnosis and Therapy
TS-015251 — Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.
Despite huge advancements in detection and treatment, cancer remains a top world health concern. One of the major limitations of current technology is adequately detecting tumor margins and micrometastases. Even with aggressive tumor resection and adjuvant chemotherapy or radiotherapy, tumor cells…
- College: College of Medicine (COM)
- Inventors: Palmieri, Dario; Croce, Carlo
- Licensing Officer: Taysavang, Panya
